AIHTA - Publications - Search - Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

Rothschedl, E. and Wolf, S. (2022): Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Oncology Fact Sheet Nr. 109.

[thumbnail of Oncology Fact Sheet Nr.109.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
92kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
Language:English
Series Name:Oncology Fact Sheet Nr. 109
Deposited on:17 Oct 2022 12:12
Last Modified:17 Oct 2022 12:12

Repository Staff Only: item control page